US 11230596
Methods for treatment of cancer comprising TIGIT-binding agents
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 11230596 (Methods for treatment of cancer comprising TIGIT-binding agents) held by MEREO BIOPHARMA 5, INC. expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- MEREO BIOPHARMA 5, INC.
- Grant date
- Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2039/55, A61P